Sarda Proteins

Why is Sarda Proteins Ltd falling/rising?

As of 17-Jul, Sarda Proteins Ltd's stock price is stable at Rs 97.78, with a year-to-date rise of 31.94%. However, the company faces significant financial challenges, including operating losses and declining net sales, which may affect its long-term viability.

As of 17-Jul, Sarda Proteins Ltd's stock price is currently stable at Rs 97.78, showing no change (0.00%). Despite this stability, the stock has demonstrated a positive performance trend over various periods, with a notable increase of 4.99% over the past week and a significant year-to-date rise of 31.94%. This performance is particularly impressive when compared to the Sensex, which has declined by 8.30% year-to-date.<BR><BR>The stock's recent performance has been bolstered by rising promoter confidence, as the promoters have increased their stake in the company by 80.66% over the previous quarter, indicating strong belief in the company's future prospects. Additionally, the stock opened with a gain of 4.99% today and reached an intraday high of Rs 97.78, reflecting positive market sentiment.<BR><BR>However, there are underlying concerns that may affect the stock's long-term viability. The company is facing operating losses, with a negative EBITDA of Rs -2.49 crore and a weak ability to service its debt, as indicated by a poor EBIT to Interest ratio of -0.58. Furthermore, the company has reported a significant decline in net sales, which fell by 60.31% over the past nine months.<BR><BR>In summary, while Sarda Proteins Ltd has shown short-term gains and positive movements in stock price due to increased promoter confidence and recent performance, the long-term outlook is clouded by financial challenges and operating losses, which could impact investor sentiment moving forward.

Which are the latest news on Sarda Proteins?

Should I buy, sell or hold Sarda Proteins Ltd?

What does Sarda Proteins do?

Sarda Proteins Ltd trades in edible oils and agri commodities, with a market cap of INR 84 Cr. The company reported net sales and net profit of 1 Cr for March 2026.

Overview: <BR>Sarda Proteins Ltd is engaged in the trading of edible oils and agri commodities, operating within the micro-cap segment of the edible oil industry.<BR><BR>History: <BR>Sarda Proteins Limited was incorporated on December 03, 1991. The company underwent a management change in FY 2018-19 following an acquisition by Ritika Vegetable Oil Private Limited. The most recent quarterly results reported net sales and net profit of 1 Cr for March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 1 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 84 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 133.00 <BR>Industry P/E: N/A <BR>Dividend Yield: 0.00% <BR>Debt Equity: -2.44 <BR>Return on Equity: 20.93% <BR>Price to Book: 26.45<BR><BR>Contact Details: <BR>Address: B-536-537, Matsya Industrial Area Alwar Rajasthan : 301030 <BR>Tel: 91-144-2881392 <BR>Email: sardaproteins@yahoo.com <BR>Website: http://www.sardaproteins.com

How big is Sarda Proteins?

As of 10th June, Sarda Proteins Ltd has a market capitalization of 84.00 Cr, with recent net sales of 16.15 Cr and a net profit of 0.63 Cr.

As of 10th June, Sarda Proteins Ltd has a market capitalization of 84.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Sarda Proteins reported Net Sales of 16.15 Cr and a Net Profit of 0.63 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 2.38 Cr and Total Assets of 2.53 Cr.

Who are in the management team of Sarda Proteins?

The management team of Sarda Proteins includes Deepak Data (Managing Director), Amit Kumar Modi (Company Secretary & Compliance Officer), Vanita Bhanot (Non-Executive & Non-Independent Director), Tarun Kumar Taunk (Non-Executive & Independent Director), and Mahavir Pratap Sharma (Non-Executive & Independent Director).

The management team of Sarda Proteins includes the following individuals:<BR><BR>1. **Deepak Data** - Managing Director<BR>2. **Amit Kumar Modi** - Company Secretary & Compliance Officer<BR>3. **Vanita Bhanot** - Non-Executive & Non-Independent Director<BR>4. **Tarun Kumar Taunk** - Non-Executive & Independent Director<BR>5. **Mahavir Pratap Sharma** - Non-Executive & Independent Director<BR><BR>If you need more details about their roles or the company, feel free to ask!

Who are the peers of the Sarda Proteins?

Sarda Proteins' peers include Ajanta Soya, Prime Industries, Raj Oil Mills, Diligent Industries, Rajgor Castor, and N K Industries. In terms of management risk, growth, and capital structure, Sarda Proteins shows average performance compared to its peers, with a 1-year return of -32.24%.

Peers: The peers of Sarda Proteins are Ajanta Soya, Prime Industries, Raj Oil Mills, Diligent Indust., Rajgor Castor, and N K Industries.<BR><BR>Quality Snapshot: Excellent management risk is observed at Ajanta Soya and Rajgor Castor, while Average management risk is found at Diligent Indust. and Sarda Proteins, with Below Average management risk at Prime Industries. Growth is Excellent at Prime Industries and Rajgor Castor, while Below Average growth is noted for Sarda Proteins and Ajanta Soya, with Average growth at Diligent Indust. Capital Structure is Excellent at Ajanta Soya and Prime Industries, Good at Sarda Proteins, and Below Average at Diligent Indust., with Rajgor Castor having Average capital structure and Raj Oil Mills and N K Industries not qualifying.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Suraj Industries at 73.56%, while the lowest is Ajanta Soya at -47.07%. Sarda Proteins has a 1-year return of -32.24%, which is better than Ajanta Soya but worse than Suraj Industries. Additionally, the six-month returns are negative for Ajanta Soya, Raj Oil Mills, Diligent Indust., and N K Industries.

When is the next results date for Sarda Proteins Ltd?

The next results date for Sarda Proteins Ltd is April 30, 2026.

The next results date for Sarda Proteins Ltd is scheduled for April 30, 2026.

How has been the historical performance of Sarda Proteins?

Sarda Proteins has shown significant sales growth, with net sales rising from 1.30 Cr in Mar'24 to 24.19 Cr in Mar'25, but faced challenges with increased expenditures, resulting in marginal operating profit and a decrease in profit after tax and EPS. Overall, while sales and total assets have grown, profitability remains a concern.

Answer:<BR>The historical performance of Sarda Proteins shows significant fluctuations in its financial metrics over the years.<BR><BR>Breakdown:<BR>Sarda Proteins experienced a notable increase in net sales, rising from 1.30 Cr in Mar'24 to 24.19 Cr in Mar'25, following a trend of varying sales figures over the previous years. The total operating income also reflected this growth, reaching 24.19 Cr in Mar'25 compared to 1.30 Cr in the prior year. However, the company faced challenges with total expenditure, which increased to 24.17 Cr in Mar'25 from 1.44 Cr in Mar'24. This resulted in a marginal operating profit of 0.02 Cr in Mar'25, a slight improvement from the losses recorded in earlier years. The profit before tax remained stable at 0.02 Cr for both Mar'25 and Mar'24, while profit after tax showed a decrease to 0.01 Cr in Mar'25 from 0.02 Cr in Mar'24. The earnings per share (EPS) also reflected this trend, decreasing to 0.06 in Mar'25 from 0.12 in Mar'24. On the balance sheet, total assets increased to 2.53 Cr in Mar'25 from 2.30 Cr in Mar'24, driven by a rise in short-term loans and advances. Overall, while Sarda Proteins has shown growth in sales and total assets, profitability metrics indicate ongoing challenges.

Is Sarda Proteins overvalued or undervalued?

As of January 6, 2025, Sarda Proteins Ltd. is considered overvalued with a "risky" rating due to high financial ratios, including a PE Ratio of 22.60 and a Price to Book Value of 9.54, despite a strong 1-year return of 62.51%.

As of 6 January 2025, Sarda Proteins Ltd. has moved from a grade of "does not qualify" to "risky," indicating a shift in its valuation outlook. The company appears to be overvalued based on its current financial ratios. The PE Ratio stands at 22.60, while the Price to Book Value is significantly high at 9.54, and the EV to Sales ratio is 21.29, all suggesting that the stock price may not be justified by its earnings or asset value.<BR><BR>In comparison to its peers, Sarda Proteins' PE ratio is higher than the industry average, which raises concerns about its valuation. Notably, its EV to EBITDA is -22.57, indicating negative earnings before interest, taxes, depreciation, and amortization, which is a significant red flag. While the company has outperformed the Sensex with a 1-year return of 62.51% compared to the Sensex's 7.57%, this performance may not be sustainable given the current valuation metrics. Overall, Sarda Proteins appears to be overvalued in the current market environment.

What is the technical trend for Sarda Proteins?

As of May 20, 2025, Sarda Proteins shows a mildly bullish trend with mixed signals from indicators like the MACD, Bollinger Bands, and RSI, suggesting caution despite the current price being at a 52-week high of 137.45.

As of 20 May 2025, the technical trend for Sarda Proteins has changed from bullish to mildly bullish. The weekly MACD and Bollinger Bands indicate a bullish stance, while the monthly RSI shows bearish momentum. Daily moving averages remain bullish, supporting the current price of 137.45, which is at a 52-week high. The KST is mildly bearish on a weekly basis but bullish monthly, and Dow Theory reflects a mildly bullish outlook in both time frames. Overall, the strength of the bullish trend is tempered by mixed signals in the RSI and KST, suggesting caution despite the positive indicators.